BMS-564929

BMS-564929 is an investigational selective androgen receptor modulator (SARM) developed by Bristol-Myers Squibb for the treatment of age-related decline in androgen levels in men ("andropause"). It is a highly potent, orally active, nonsteroidal tissue selective modulator that binds to the androgen receptor with a Ki value of 2.11 nM. The compound is approximately 400-fold selective for androgen receptors versus progesterone receptors and more than 1000-fold selective versus glucocorticoid, mineralocorticoid, and estrogen receptors. In preclinical studies, BMS-564929 demonstrated substantially higher potency than testosterone in promoting muscle growth while showing high selectivity for muscle versus prostate tissue, potentially offering a more favorable safety profile than traditional testosterone therapy.

Other names

4-[(7R,7aS)-7-hydroxy-1,3-dioxo-hexahydro-1H-pyrrolo[1,2-c]imidazol-2-yl]-2-chloro-3-methylbenzonitrile2-Chloro-3-methyl-4-[(7R,7AS)-tetrahydro-7-hydroxy-1,3-dioxo-1H-pyrrolo[1,2-c]imidazol-2(3H)-yl]benzonitrile(7R,7aS)-2-(3-Chloro-4-cyano-2-methylphenyl)-7-hydroxytetrahydro-2H-pyrrolo(1,2-e)imidazole-1,3-dione